Auf dieser Seite
SNDX Syndax Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 4, 2026
$17,60
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$12,9952-Wochen-Tief
$25,5952-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.57B
P/E (TTM)
-7.0
EPS (TTM)
$-2.51
Umsatz (TTM)
$252M
Ihre Abzeichen
52W-Spanne
$13–$26
Analystenbewertung
BUY
Kursziel
$38
P/E
-7.0
ROE
-255.9%
Nettogewinnmarge
-87.6%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
SNDX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$17.60
Marktkapitalisierung (MRQ)
$1.57B
P/E (TTM)
-7.0
EPS (TTM)
$-2.51
Umsatz (TTM)
$252M
ROE (TTM)
-255.9%
Verschuldungsgrad (MRQ)
23.2
52W-Spanne
$13–$26
SNDX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$172M2016-12-31 → 2025-12-31
EPS$-3.292019-12-31 → 2025-12-31
Freier Cashflow$-323M2016-12-31 → 2025-12-31
Nettogewinnmarge-87.6%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | SNDX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -7.05-Jahres-Durchschnitt ≈4.0 | ≈4.0 | · | · | |
| P/S (TTM) | 6.25-Jahres-Durchschnitt ≈22.4 | ≈22.4 | 62.1 | Unterbewertet | |
| K/B (MRQ) | 103.95-Jahres-Durchschnitt ≈8.5 | ≈8.5 | 5.7 | Überbewertet | |
| EV / EBITDA | -5.5 | · | · | · | |
| Price / FCF (Kurs / FCF) | -4.85-Jahres-Durchschnitt ≈2.9 | ≈2.9 | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -4.85-Jahres-Durchschnitt ≈1.4 | ≈1.4 | · | · | |
| EV / Umsatz (TTM) | 5.4 | · | · | · | |
| EV / FCF | -4.6 | · | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 23.85-Jahres-Durchschnitt ≈8.5 | ≈8.5 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | SNDX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -77.1%5-Jahres-Durchschnitt ≈-524.7% | ≈-524.7% | -1024.8% | Spitzenklasse | |
| EBITDA Margin (EBITDA-Marge) | -158.4%5-Jahres-Durchschnitt ≈-524.7% | ≈-524.7% | -1024.8% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | -87.6%5-Jahres-Durchschnitt ≈-498.0% | ≈-498.0% | -1048.0% | Spitzenklasse | |
| ROA (TTM) | -34.0%5-Jahres-Durchschnitt ≈-31.2% | ≈-31.2% | -40.6% | Schwach | |
| ROE (TTM) | -255.9%5-Jahres-Durchschnitt ≈-85.8% | ≈-85.8% | -44.0% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | SNDX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 23.2 | · | 0.1 | Hohe Verschuldung | |
| Liquiditätsgrad (MRQ) | 6.85-Jahres-Durchschnitt ≈11.7 | ≈11.7 | 7.2 | Im Einklang | |
| Quick Ratio | 3.65-Jahres-Durchschnitt ≈11.3 | ≈11.3 | 5.1 | Im Einklang |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | SNDX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 627.8% | · | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -44.7% | · | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 157.7% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | SNDX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.35-Jahres-Durchschnitt ≈0.2 | ≈0.2 | 0.1 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 7.6 | · | 5.8 | Spitzenklasse | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$578.4K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
3.0%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 3, 2026 | $-0.55 | $-0.45 | -21.9% |
| 31. März 2026 | Mai 11, 2026 | $-0.48 | $-0.59 | 19.2% |
| 31. Dezember 2025 | $-0.78 | $-0.60 | -30.9% | |
| 30. September 2025 | $-0.70 | $-0.73 | 4.2% | |
| 30. Juni 2025 | $-0.83 | $-1.04 | 19.9% | |
| 31. März 2025 | $-0.98 | $-1.36 | 27.8% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172M | $24M | $0 | $0 | $140M | $2M | $2M | $2M | $2M | $1M | $627.0K | |
| R&D Expense | $259M | $242M | $163M | $118M | $88M | $50M | $43M | $60M | $48M | $32M | $10M | |
| SG&A Expense | $180M | $121M | $67M | $33M | $25M | $23M | $16M | $17M | $16M | $13M | $12M | |
| Operating Expenses | $445M | $363M | $230M | $152M | $113M | $73M | $59M | $77M | $64M | $45M | $21M | |
| Operating Income | $-273M | $-340M | $-230M | $-152M | $26M | $-71M | $-58M | $-76M | $-62M | $-44M | $-21M | |
| Interest Expense | · | · | $208.0K | $3M | $2M | $2M | · | · | · | · | · | |
| Interest Income | $23M | $26M | $21M | $6M | $403.0K | $841.0K | $2M | $2M | · | · | · | |
| Other Non-op | $-1M | $-247.0K | $-361.0K | $-316.0K | $202.0K | $-219.0K | $-79.0K | $-27.0K | $-269.0K | $41.0K | $-37.0K | |
| Income Tax | $433.0K | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-285M | $-319M | $-209M | $-149M | $25M | $-73M | $-56M | $-74M | $-61M | $-44M | $-24M | |
| EPS (Basic) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.48 | $-1.87 | $-1.84 | · | · | · | · | |
| EPS (Diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 | $-1.87 | $-1.84 | · | · | · | · | |
| Shares (Basic) | 86,625,610 | 85,622,065 | 70,370,519 | 60,760,906 | 52,064,809 | 41,308,242 | 30,490,783 | · | · | · | · | |
| Shares (Diluted) | 86,625,610 | 85,622,065 | 70,370,519 | 60,760,906 | 53,622,904 | 41,308,242 | 30,490,783 | · | · | · | · | |
| EBITDA | $-273M | $-340M | $-230M | $-152M | $26M | · | $-58M | · | $-62M | $-44M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $154M | $295M | $74M | $222M | $115M | $25M | $34M | $35M | $24M | $23M | |
| Short-term Investments | $259M | $419M | $275M | $401M | $218M | $178M | $35M | $47M | $95M | $81M | $63M | |
| Receivables | $38M | $8M | $0 | · | · | · | · | · | · | · | · | |
| Inventory | $33M | $366.0K | $0 | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $13M | $9M | $3M | $2M | $1M | $6M | $3M | $2M | $3M | $3M | $1M | |
| Other Current Assets | · | · | $0 | · | · | · | · | · | · | · | · | |
| Current Assets | $528M | $603M | $581M | $490M | $448M | $299M | $62M | $83M | $133M | $109M | $88M | |
| PP&E (Net) | $181.0K | $0 | $8.0K | $20.0K | $278.0K | $192.0K | $281.0K | $373.0K | $267.0K | $260.0K | $88.0K | |
| PP&E (Gross) | $606.0K | $419.0K | $419.0K | $419.0K | $721.0K | $591.0K | $591.0K | $608.0K | $466.0K | $540.0K | $280.0K | |
| Accum. Depreciation | $425.0K | $419.0K | $411.0K | $399.0K | $443.0K | $399.0K | $310.0K | $235.0K | $199.0K | $280.0K | $192.0K | |
| Other Non-current Assets | · | $0 | $463.0K | $807.0K | $0 | $1M | $197.0K | $219.0K | $231.0K | $243.0K | $2M | |
| Total Assets | $530M | $725M | $613M | $497M | $450M | $301M | $64M | $84M | $137M | $109M | $90M | |
| Accounts Payable | $17M | $12M | $10M | $4M | $6M | $4M | $6M | $1M | $2M | $2M | $1M | |
| Current Liabilities | $120M | $104M | $58M | $29M | $21M | $19M | $18M | $16M | $16M | $10M | $5M | |
| Capital Leases | · | $2M | $578.0K | $709.0K | $711.0K | $101.0K | $419.0K | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | $1.0K | $5.0K | $136.0K | $310.0K | $288.0K | $70.0K | |
| Total Liabilities | $465M | $437M | $59M | $30M | $41M | $48M | $32M | $31M | $33M | $25M | $23M | |
| Total Debt | $350M | $338M | · | · | · | · | · | · | · | · | · | |
| Common Stock | $9.0K | $9.0K | $8.0K | $7.0K | $6.0K | $5.0K | $3.0K | $2.0K | $2.0K | $2.0K | $1.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | $471M | · | · | |
| Retained Earnings | $-1.51B | $-1.22B | $-902M | $-693M | $-544M | $-569M | $-495M | $-439M | $-366M | $-305M | $-260M | |
| Stockholders' Equity | $65M | $288M | $554M | $467M | $408M | $252M | $32M | $53M | $104M | $84M | $-252M | |
| Liabilities + Equity | $530M | $725M | $613M | $497M | $450M | $301M | $64M | $84M | $137M | $109M | $90M | |
| Shares Outstanding | 87,405,979 | 85,694,443 | 84,826,632 | 68,111,385 | 54,983,105 | 47,881,223 | 27,140,484 | 24,835,951 | 24,390,033 | 18,215,181 | 85,440 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $48M | $43M | $31M | $16M | $13M | $9M | $6M | $6M | $5M | $5M | $4M | |
| Operating Cash Flow | $-323M | $-275M | $-161M | $-134M | $29M | $-71M | $-51M | $-69M | $-47M | $-35M | $-2M | |
| CapEx | $187.0K | $0 | $0 | $0 | $129.0K | $0 | · | $187.0K | $84.0K | $261.0K | $49.0K | |
| Investing Cash Flow | $290M | $-220M | $118M | $-186M | $-41M | $-143M | $13M | $51M | $-17M | $-18M | · | |
| Financing Cash Flow | $14M | $353M | $264M | $172M | $118M | $304M | $29M | $16M | $76M | $54M | · | |
| Net Change in Cash | $-19M | $-141M | $221M | $-148M | $107M | $91M | $-9M | $-1M | $11M | $762.0K | $13M | |
| Taxes Paid | $150 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-323M | · | $-161M | $-134M | $29M | · | · | · | $-47M | $-35M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -158.4% | -1434.4% | · | · | 18.8% | · | -3792.9% | · | -2939.0% | -3587.4% | · | |
| Net Margin | -165.6% | -1346.1% | · | · | 17.8% | · | -3694.6% | · | -2884.3% | -3645.2% | · | |
| EBITDA Margin | -158.4% | -1434.4% | · | · | 18.8% | · | -3792.9% | · | -2939.0% | -3587.4% | · | |
| ROA | -45.5% | -47.7% | -37.7% | -31.5% | 6.6% | · | -76.0% | · | -49.4% | -44.7% | · | |
| ROE | -257.1% | -97.4% | -45.8% | -37.1% | 8.2% | · | -148.2% | · | -64.5% | 52.9% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.4 | 5.8 | 10.0 | 16.9 | 21.7 | · | 3.4 | · | 8.4 | 10.5 | · | |
| Quick Ratio | 3.6 | 5.6 | 9.8 | 16.4 | 21.3 | · | 3.3 | · | 8.2 | 10.2 | · | |
| Debt / Equity | 5.4 | 1.2 | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1105.5 | -48.4 | 13.8 | · | · | · | · | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.0 | 0.0 | · | 0.4 | · | 0.0 | · | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.6 | 6.2 | · | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.74 | $3.36 | $6.53 | $6.86 | $7.43 | · | $1.16 | · | $4.28 | $4.62 | · | |
| Revenue / Share | $1.99 | $0.28 | $0.00 | · | $2.61 | · | · | · | · | · | · | |
| Cash Flow / Share | $-3.73 | $-3.21 | $-2.28 | $-2.20 | $0.54 | · | · | · | · | · | · | |
| Cash / Share | $1.54 | $1.80 | $3.48 | $1.09 | $4.04 | · | $0.91 | · | $1.44 | $1.31 | · | |
| EPS (TTM) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 | $-1.87 | $-1.84 | · | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 627.8% | · | · | · | 9109.6% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | -44.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 157.7% | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $172M | $24M | $0 | $0 | $140M | $2M | $2M | $2M | $2M | $1M | · | |
| Net Income TTM | $-285M | $-319M | $-209M | $-149M | $25M | $-73M | $-56M | $-74M | $-61M | $-44M | · | |
| Market Cap | $1.84B | $1.13B | $1.83B | $1.73B | $1.20B | · | $238M | · | $214M | $131M | · | |
| Enterprise Value | $1.79B | $898M | · | · | · | · | · | · | · | · | · | |
| P/E | -6.4 | -3.6 | -7.3 | -10.3 | 47.6 | -11.9 | -4.8 | · | · | · | · | |
| P/S | 10.7 | 47.8 | · | · | 8.6 | · | 157.1 | · | 101.4 | 107.1 | · | |
| P/B | 28.4 | 3.9 | 3.3 | 3.7 | 2.9 | · | 7.5 | · | 2.0 | 1.6 | · | |
| P / Tangible Book | 28.4 | 3.9 | 3.3 | 3.7 | 2.9 | 4.2 | · | · | · | · | · | |
| P / Cash Flow | -5.7 | -4.1 | -11.4 | -13.0 | 41.3 | · | -4.7 | · | -4.5 | -3.7 | · | |
| P / FCF | -5.7 | · | -11.4 | -13.0 | 41.5 | · | · | · | -4.5 | -3.7 | · | |
| EV / EBITDA | -6.6 | -2.6 | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -5.5 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 10.4 | 37.9 | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -15.7% | -28.1% | -13.8% | -9.7% | 2.1% | -8.4% | -21.0% | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73M | $65M | $68M | $46M | $38M | $20M | $8M | $12M | $4M | $0 | $0 | $0 | · | · | · | · | |
| R&D Expense | $68M | $59M | $79M | $56M | $62M | $62M | $66M | $71M | $49M | $56M | $39M | $35M | $34M | $27M | $30M | $30M | |
| SG&A Expense | $42M | $38M | $50M | $45M | $44M | $41M | $38M | $31M | $29M | $23M | $17M | $15M | $12M | $8M | $8M | $7M | |
| Operating Expenses | $113M | $99M | $131M | $103M | $107M | $104M | $104M | $102M | $78M | $80M | $56M | $50M | $46M | $35M | $38M | $37M | |
| Operating Income | $-40M | $-34M | $-63M | $-57M | $-69M | $-84M | $-96M | $-90M | $-74M | $-80M | $-56M | $-50M | $-46M | $-35M | $-38M | $-37M | |
| Interest Expense | · | · | · | · | · | · | · | · | $45.0K | $55.0K | $70.0K | $35.0K | $40.0K | $2M | $695.0K | $651.0K | |
| Interest Income | $4M | $4M | $4M | $5M | $6M | $7M | $7M | $5M | $6M | $7M | $5M | $5M | $5M | $2M | $878.0K | $224.0K | |
| Other Non-op | $-438.0K | $-186.0K | $3M | $-275.0K | $-586.0K | $-221.0K | $-14M | $32.0K | $6M | $7M | $-66.0K | $-93.0K | $-147.0K | $-295.0K | $-31.0K | $116.0K | |
| Income Tax | $0 | $0 | $433.0K | $0 | $0 | $0 | · | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $-49M | $-43M | $-68M | $-61M | $-72M | $-85M | $-94M | $-84M | $-68M | $-72M | $-51M | $-45M | $-41M | $-35M | $-38M | $-37M | |
| EPS (Basic) | $-0.55 | $-0.48 | $-0.78 | $-0.70 | $-0.83 | $-0.98 | $-1.09 | $-0.98 | $-0.80 | $-0.85 | $-0.73 | $-0.64 | $-0.59 | $-0.58 | $-0.62 | $-0.63 | |
| EPS (Diluted) | $-0.55 | $-0.48 | $-0.78 | $-0.70 | $-0.83 | $-0.98 | $-1.09 | $-0.98 | $-0.80 | $-0.85 | $-0.73 | $-0.64 | $-0.59 | $-0.58 | $-0.62 | $-0.63 | |
| Shares (Basic) | 88,991,317 | 88,255,636 | · | 86,620,992 | 86,337,237 | 86,171,889 | · | 85,433,569 | 85,274,829 | 85,213,200 | 69,855,766 | 69,638,427 | 69,438,890 | 60,670,294 | 60,156,653 | 58,978,615 | |
| Shares (Diluted) | 88,991,317 | 88,255,636 | · | 86,620,992 | 86,337,237 | 86,171,889 | · | 85,433,569 | 85,274,829 | 85,213,200 | 69,855,766 | 69,638,427 | 69,438,890 | 60,670,294 | 60,156,653 | 58,978,615 | |
| EBITDA | $-40M | $-34M | · | $-57M | $-69M | $-84M | · | $-90M | $-74M | $-80M | $-56M | $-50M | $-46M | $-35M | $-38M | $-37M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $336M | $131M | $135M | $117M | $109M | $154M | $154M | $133M | $105M | $115M | $95M | $97M | $58M | $71M | $120M | $189M | |
| Short-term Investments | $211M | $221M | $259M | $319M | $347M | $358M | $419M | $257M | $320M | $320M | $269M | $302M | $375M | $266M | $247M | $209M | |
| Receivables | · | · | $38M | · | · | · | $8M | · | · | · | · | · | · | · | · | · | |
| Inventory | $33M | $35M | $33M | $25M | $18M | $5M | $366.0K | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $16M | $13M | $10M | $10M | $8M | $9M | $5M | $4M | $5M | $4M | $3M | $2M | $2M | $2M | $9M | |
| Other Current Assets | · | · | · | · | · | · | · | $4M | $10M | $6M | · | · | · | · | · | · | |
| Current Assets | $675M | $471M | $528M | $530M | $532M | $549M | $603M | $415M | $446M | $454M | $381M | $409M | $442M | $358M | $392M | $420M | |
| PP&E (Net) | $212.0K | $177.0K | $181.0K | $128.0K | $0 | $0 | $0 | $0 | $2.0K | $5.0K | $10.0K | $13.0K | $17.0K | $23.0K | $256.0K | $266.0K | |
| PP&E (Gross) | $646.0K | $606.0K | $606.0K | · | · | · | $419.0K | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $434.0K | $429.0K | $425.0K | · | · | · | $419.0K | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | · | · | · | · | · | · | · | $0 | $156.0K | $248.0K | $587.0K | $579.0K | $693.0K | $881.0K | $995.0K | $1M | |
| Total Assets | $704M | $473M | $530M | $552M | $596M | $641M | $725M | $426M | $477M | $543M | $399M | $431M | $460M | $360M | $406M | $422M | |
| Accounts Payable | $5M | $11M | $17M | $14M | $17M | $10M | $12M | $5M | $12M | $9M | $6M | $11M | $8M | $7M | $6M | $8M | |
| Current Liabilities | $100M | $86M | $120M | $114M | $113M | $95M | $104M | $59M | $42M | $51M | $39M | $30M | $24M | $21M | $31M | $31M | |
| Capital Leases | · | · | · | · | · | · | · | $0 | $133.0K | $327.0K | $851.0K | $1M | $588.0K | $768.0K | $570.0K | $643.0K | |
| Total Liabilities | $689M | $431M | $465M | $436M | $439M | $426M | $437M | $59M | $43M | $51M | $40M | $31M | $24M | $22M | $44M | $48M | |
| Total Debt | $350M | $350M | · | $327M | $331M | $336M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $-1.60B | $-1.55B | $-1.51B | $-1.44B | $-1.38B | $-1.31B | $-1.22B | $-1.13B | $-1.04B | $-975M | $-830M | $-779M | $-734M | $-654M | $-618M | $-581M | |
| Stockholders' Equity | $15M | $42M | $65M | $115M | $157M | $215M | $288M | $366M | $434M | $492M | $359M | $400M | $436M | $338M | $362M | $375M | |
| Liabilities + Equity | $704M | $473M | $530M | $552M | $596M | $641M | $725M | $426M | $477M | $543M | $399M | $431M | $460M | $360M | $406M | $422M | |
| Shares Outstanding | 89,150,619 | 88,543,881 | 87,405,979 | 86,905,343 | 86,059,077 | 86,047,032 | 85,694,443 | 85,571,205 | 85,028,629 | 84,979,686 | 69,638,168 | 69,431,198 | 68,495,426 | 60,122,661 | 56,399,734 | 55,030,890 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $14M | $12M | $11M | $12M | $14M | $10M | $12M | $12M | $10M | $9M | $8M | $8M | $6M | $4M | $4M | $3M | |
| Operating Cash Flow | $-30M | $-50M | $-69M | $-71M | $-88M | $-95M | $-57M | $-62M | $-72M | $-84M | $-45M | $-35M | $-39M | $-29M | $-40M | $-42M | |
| Investing Cash Flow | $-17M | $38M | $82M | $72M | $42M | $94M | $-269M | $87M | $62M | $-99M | $40M | $74M | $20M | $-7M | $-50M | $8M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $0 | · | · | |
| Financing Cash Flow | $253M | $8M | $6M | $6M | $551.0K | $930.0K | $347M | $3M | $676.0K | $2M | $2M | $1M | $2M | $-14M | $22M | $557.0K | |
| Net Change in Cash | $206M | $-4M | $18M | $8M | $-45M | $-90.0K | $21M | $28M | $-9M | $-181M | $-3M | $40M | $-17M | $-49M | $-69M | $-33M |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -54.9% | -52.7% | · | -125.2% | -182.7% | -417.9% | · | -716.6% | -2120.5% | · | · | · | · | · | · | · | |
| Net Margin | -67.8% | -65.8% | · | -132.4% | -189.3% | -423.3% | · | -673.0% | -1944.7% | · | · | · | · | · | · | · | |
| EBITDA Margin | -54.9% | -52.7% | · | -125.2% | -182.7% | -417.9% | · | -716.6% | -2120.5% | · | · | · | · | · | · | · | |
| ROA | -7.6% | -7.7% | · | -12.4% | -13.4% | -14.3% | · | -20.4% | -15.0% | -14.4% | -13.5% | -10.7% | -9.3% | -11.8% | -11.2% | -10.6% | |
| ROE | -57.2% | -33.2% | · | -25.2% | -24.3% | -24.0% | · | -23.2% | -16.3% | -15.6% | -14.7% | -11.7% | -10.2% | -13.2% | -13.0% | -12.3% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.8 | 5.5 | · | 4.6 | 4.7 | 5.8 | · | 7.0 | 10.5 | 8.9 | 9.7 | 13.6 | 18.6 | 17.2 | 12.7 | 13.7 | |
| Quick Ratio | 5.5 | 4.1 | · | 3.8 | 4.0 | 5.4 | · | 6.6 | 10.0 | 8.6 | 9.3 | 13.2 | 18.2 | 16.2 | 11.9 | 13.0 | |
| Debt / Equity | 23.2 | 8.4 | · | 2.8 | 2.1 | 1.6 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -1649.2 | -1445.7 | -805.1 | -1419.4 | -1150.4 | -20.1 | -54.3 | -56.6 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.17 | $0.47 | · | $1.33 | $1.83 | $2.50 | · | $4.28 | $5.11 | $5.79 | $5.16 | $5.76 | $6.36 | $5.62 | $6.42 | $6.81 | |
| Revenue / Share | $0.82 | $0.73 | · | $0.53 | $0.44 | $0.23 | · | $0.15 | $0.04 | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.57 | · | · | · | $-1.10 | · | · | · | $-0.98 | · | · | $-0.56 | · | · | · | |
| Cash / Share | $3.77 | $1.48 | · | $1.34 | $1.26 | $1.79 | · | $1.55 | $1.24 | $1.35 | $1.36 | $1.40 | $0.84 | $1.19 | $2.13 | $3.43 | |
| EPS (TTM) | $-2.51 | $-2.79 | · | $-3.60 | $-3.88 | $-3.85 | · | $-3.65 | $-3.40 | $-3.24 | $-2.59 | $-2.44 | $-2.42 | $0.01 | $0.19 | $0.37 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $252M | $217M | · | $112M | $78M | $44M | · | $16M | $4M | $0 | · | · | $140M | $140M | $140M | $140M | |
| Net Income TTM | $-221M | $-243M | · | $-312M | $-335M | $-331M | · | $-297M | $-264M | $-241M | $-176M | $-160M | $-153M | $-14M | $818.0K | $15M | |
| Market Cap | $1.95B | $2.07B | · | $1.34B | $806M | $1.06B | · | $1.65B | $1.75B | $2.02B | $1.01B | $1.45B | $1.45B | $1.44B | $1.09B | $956M | |
| Enterprise Value | $1.75B | $2.07B | · | $1.23B | $681M | $881M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -8.7 | -8.4 | · | -4.3 | -2.4 | -3.2 | · | -5.3 | -6.0 | -7.3 | -5.6 | -8.6 | -8.7 | 2403.0 | 101.3 | 47.0 | |
| P/S | 7.7 | 9.5 | · | 12.0 | 10.3 | 24.2 | · | 103.0 | 498.8 | · | · | · | 10.4 | 10.3 | 7.8 | 6.8 | |
| P/B | 129.1 | 49.7 | · | 11.6 | 5.1 | 4.9 | · | 4.5 | 4.0 | 4.1 | 2.8 | 3.6 | 3.3 | 4.3 | 3.0 | 2.6 | |
| P / Tangible Book | 129.1 | 49.7 | · | 11.6 | 5.1 | 4.9 | · | 4.5 | 4.0 | 4.1 | 2.8 | 3.6 | 3.3 | 4.3 | 3.0 | 2.6 | |
| P / Cash Flow | · | -41.1 | · | · | · | -11.1 | · | · | · | -24.2 | · | · | -36.9 | · | · | -22.8 | |
| EV / Revenue | 6.9 | 9.5 | · | 11.0 | 8.7 | 20.1 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -11.5% | -11.9% | · | -23.4% | -41.4% | -31.3% | · | -19.0% | -16.6% | -13.6% | -17.8% | -11.7% | -11.5% | 0.04% | 0.99% | 2.1% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $172M | $24M | $0 | $0 | $140M |
| Betriebsgewinnmarge % | -158.4% | -1434.4% | · | · | 18.8% |
| Nettoergebnis | $-285M | $-319M | $-209M | $-149M | $25M |
| Verwässerte EPS | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 5.4 | 1.2 | · | · | · |
| Liquiditätsgrad | 4.4 | 5.8 | 10.0 | 16.9 | 21.7 |
| Quick Ratio | 3.6 | 5.6 | 9.8 | 16.4 | 21.3 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-323M | · | $-161M | $-134M | $29M |
Institutionelle Eigentümer (13F) 262 Einreicher · $2.5B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
262
Gehaltener Wert
$2.5B
Neue Positionen
37
Geschlossene Positionen
36
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 37 (-10 vs. Vorquartal) | 36 (+11 vs. Vorquartal) | 93 (-3 vs. Vorquartal) | 82 (+6 vs. Vorquartal) | +8.7M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $197.177.353 | 9.020.006 | 7,88% | Aktien |
| Kynam Capital Management, LP | $175.993.964 | 8.050.959 | 7,03% | Aktien |
| VANGUARD GROUP INC | $130.899.317 | 6.230.334 | 5,23% | Aktien |
| GOLDMAN SACHS GROUP INC | $128.127.253 | 5.861.265 | 5,12% | Aktien |
| STATE STREET CORP | $123.693.149 | 5.658.424 | 4,94% | Aktien |
| BANK OF AMERICA CORP /DE/ | $88.425.755 | 4.045.094 | 3,53% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $85.863.719 | 3.927.892 | 3,43% | Aktien |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $82.628.614 | 3.779.900 | 3,30% | Aktien |
| Eversept Partners, LP | $61.168.871 | 2.798.210 | 2,44% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $56.499.563 | 2.584.136 | 2,26% | Aktien |
| Hood River Capital Management LLC | $56.055.139 | 2.564.279 | 2,24% | Aktien |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $54.650.000 | 2.500.000 | 2,18% | Aktien |
| FRANKLIN RESOURCES INC | $49.982.872 | 2.286.499 | 2,00% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $44.899.566 | 2.053.960 | 1,79% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $42.010.461 | 1.921.796 | 1,68% | Aktien |
| UBS Group AG | $41.397.375 | 1.893.750 | 1,65% | Aktien |
| Elmind Capital, LP | $40.550.300 | 1.855.000 | 1,62% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $39.133.182 | 1.790.173 | 1,56% | Aktien |
| Candriam S.C.A. | $37.039.763 | 1.696.040 | 1,48% | Aktien |
| Soleus Capital Management, L.P. | $35.588.933 | 1.628.039 | 1,42% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $34.497.812 | 1.578.125 | 1,38% | Aktien |
| ORBIMED ADVISORS LLC | $33.708.120 | 1.542.000 | 1,35% | Aktien |
| Nuveen, LLC | $29.829.610 | 1.364.575 | 1,19% | Aktien |
| MPM BIOIMPACT LLC | $29.150.813 | 1.333.523 | 1,16% | Aktien |
| Aisling Capital Management LP | $28.785.379 | 1.316.806 | 1,15% | Aktien |
| Woodline Partners LP | $27.341.614 | 1.250.760 | 1,09% | Aktien |
| D. E. Shaw & Co., Inc. | $27.105.395 | 1.239.954 | 1,08% | Aktien |
| Catalio Capital Management, LP | $26.575.158 | 1.215.698 | 1,06% | Aktien |
| SILVERARC CAPITAL MANAGEMENT, LLC | $26.546.565 | 1.214.390 | 1,06% | Aktien |
| Prosight Management, LP | $26.232.000 | 1.200.000 | 1,05% | Aktien |
| Trails Edge Capital Partners, LP | $24.264.600 | 1.110.000 | 0,97% | Aktien |
| ALGERT GLOBAL LLC | $22.985.025 | 1.051.465 | 0,92% | Aktien |
| Bank of New York Mellon Corp | $22.736.118 | 1.040.079 | 0,91% | Aktien |
| SPHERA FUNDS MANAGEMENT LTD. | $22.179.287 | 1.014.606 | 0,89% | Aktien |
| LOOMIS SAYLES & CO L P | $20.190.420 | 923.624 | 0,81% | Aktien |
| Parkman Healthcare Partners LLC | $19.176.816 | 877.256 | 0,77% | Aktien |
| Ensign Peak Advisors, Inc | $18.970.786 | 867.831 | 0,76% | Aktien |
| Palo Alto Investors LP | $18.908.594 | 864.986 | 0,76% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $18.653.226 | 853.304 | 0,75% | Aktien |
| NORTHERN TRUST CORP | $18.483.439 | 845.537 | 0,74% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17.800.664 | 814.303 | 0,71% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $13.848.507 | 633.509 | 0,55% | Aktien |
| TWO SIGMA ADVISERS, LP | $13.294.120 | 632.752 | 0,53% | Aktien |
| MORGAN STANLEY | $12.875.080 | 588.979 | 0,51% | Aktien |
| Rhenman & Partners Asset Management AB | $12.247.065 | 560.250 | 0,49% | Aktien |
| Apis Capital Advisors, LLC | $12.154.160 | 556.000 | 0,49% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $11.946.862 | 546.517 | 0,48% | Aktien |
| Qube Research & Technologies Ltd | $10.431.199 | 477.182 | 0,42% | Aktien |
| FIRST TRUST ADVISORS LP | $9.983.462 | 456.700 | 0,40% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $9.926.648 | 454.101 | 0,40% | Aktien |
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Access Industries Holdings LLC, AI Life Sciences Investments LLC, AI LSI-SPV LLC, Access Industries Holdings (BVI) L.P., Access Industries, LLC, Access Industries Management, LLC, Len Blavatnik ×2 Einreichungen | 4. März 2022 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 25 Insider · 11 Führungskräfte · 15 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael A Metzger | Chief Executive Officer | 8. Juli 2026 M | 484.843 | 0 | 4 | $-1.428.484 |
| Keith A. Goldan | Chief Financial Officer | 1. Juni 2026 S | 139.252 | 0 | 3 | $-136.994 |
| Daphne Karydas | Chief Financial Officer | 3. Februar 2021 A | · | 0 | 0 | $0 |
| Richard P Shea | Chief Financial Officer | 12. Februar 2020 A | 7.121 | 0 | 0 | $0 |
| Neil Gallagher | President, Head of R&D | 10. Februar 2025 S | 85.095 | 0 | 0 | $0 |
| Nicholas A.J. Botwood | Head of R&D, CMO | 12. Juni 2026 M | 60.885 | 0 | 2 | $-1.183.643 |
| Peter Ordentlich | Chief Scientific Officer | 15. Februar 2023 M | 0 | 0 | 0 | $0 |
| Catherine Madigan | Chief Medical Officer | 2. Februar 2023 A | · | 0 | 0 | $0 |
| Alexander Nolte | Chief Accounting Officer | 2. Februar 2023 A | 0 | 0 | 0 | $0 |
| Steve M Sabus | Chief Commercial Officer | 5. Dezember 2022 A | · | 0 | 0 | $0 |
| Michael L. Meyers | SVP, Chief Medical Officer | 2. Februar 2022 A | 23.280 | 0 | 0 | $0 |
| Aleksandra Rizo | Direktor | 4. Februar 2026 A | 49.000 | 0 | 0 | $0 |
| Jennifer Jarrett | Direktor | 4. Februar 2026 A | 114.000 | 0 | 0 | $0 |
| Martin H. Huber Jr. | Direktor | 4. Februar 2026 A | 103.000 | 0 | 0 | $0 |
| Pierre Legault | Direktor | 4. Februar 2026 A | 114.000 | 0 | 0 | $0 |
| Keith Katkin | Direktor | 4. Februar 2026 A | 124.000 | 0 | 0 | $0 |
| Dennis Podlesak | Direktor | 4. Februar 2026 A | 239.763 | 0 | 0 | $0 |
| William Meury | Direktor | 5. Februar 2025 A | 90.000 | 0 | 0 | $0 |
| Briggs Morrison | Direktor | 7. Februar 2024 A | 34.836 | 0 | 0 | $0 |
| Fabrice Egros | Direktor | 2. Februar 2022 A | 32.000 | 0 | 0 | $0 |
| Henry Chen | Direktor | 23. Mai 2018 A | · | 0 | 0 | $0 |
| Luke Evnin | Direktor | 23. Mai 2018 A | 2.168.691 | 0 | 0 | $0 |
| George W. Sledge Jr. | Direktor | 17. Mai 2017 A | · | 0 | 0 | $0 |
| Ivor Royston | Direktor | 20. März 2017 D | 625.545 | 0 | 0 | $0 |
| Kim P. Kamdar | Direktor | 31. Oktober 2016 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 28 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,44% | 74.364 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,46% | 119.538 NS | 31. Juli 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,35% | 236.318 NS | 31. Juli 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,13% | 1.633 NS | 31. Juli 2026 | N-PORT |
| ESSC · Strategy Shares | 0,11% | 2.142 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,11% | 614.605 SH | 11. September 2026 | Täglich |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 79.812 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,11% | 104.684 SH | 19. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,11% | 95.455 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,11% | 836.007 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,11% | 6.329 SH | 2. Oktober 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 21.409 NS | 31. Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,06% | 22.921 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,06% | 512.404 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,05% | 2.273.181 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,05% | 42.552 NS | 31. Juli 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,05% | 76.659 SH | 2. Oktober 2026 | Täglich |
| ISCG · iShares Trust | 0,05% | 26.742 SH | 11. September 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,03% | 252.202 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 40.330 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 1.013.279 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,01% | 4.637 SH | 11. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,01% | 6.640 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 120.018 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 20.189 SH | 11. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2.825.144 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.016 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 3.791 SH | 11. September 2026 | Täglich |
SNDX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 19 Analysten
KAUF
Median-Ziel
$37.00
+110,2%
8 42,1%
Starker Kauf
10 52,6%
Kauf
1 5,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
11 Analysten · 2026-09-30Mittelwert-Ziel $37.55 +113,3%
← Unter allen Zielen
Aktueller Preis $17.60
Tief$26.00
Mittelwert$37.55
Hoch$57.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | · |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | · |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | · |
| XNCR | $1.10B | -12.3 | 13.7% | -73.2% | -14.0% | · |
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | · |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | · |
| COAG | · | · | · | · | · | · |
| ANAB | · | -105.4 | 157.0% | · | · | · |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Dieser Biotech-Aktien-Gewinner ist um 72 % gestiegen, aber ein Abverkauf von 4 Millionen US-Dollar deutet auf einen leichten Reset hin
Nasdaq · 6 Monate, 1 Woche vor
Biotech-Aktie steigt um 72 %, $8 Millionen Verkauf, aber hier ist der Grund, warum ein Fonds immer noch bullish scheint
Nasdaq · 6 Monate, 1 Woche vor
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 4, 2026